Should an 87-year-old patient with cardiomyopathy who is taking sacubitril/valsartan (Entresto) receive the yellow-fever vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yellow Fever Vaccination in an 87-Year-Old with Cardiomyopathy on Entresto

This patient should generally NOT receive the yellow fever vaccine unless travel to a high-risk endemic area is absolutely unavoidable, in which case a medical waiver should be provided instead.

Primary Reasoning

The decision is driven by age-related mortality risk, not by the Entresto medication itself:

Age as a Critical Risk Factor

Age ≥60 years is a formal precaution for yellow fever vaccination, and at 87 years old, this patient faces substantially elevated risks 1:

  • Serious adverse event rate: 8.3 per 100,000 doses in persons ≥60 years vs. 4.7 per 100,000 for all recipients
  • Risk is 7.5 times higher in those ≥60 years compared to the 19-29 year reference group
  • Yellow fever vaccine-associated viscerotropic disease (YEL-AVD): 1.4 per 100,000 (vs. 0.4 overall)
  • Yellow fever vaccine-associated neurotropic disease (YEL-AND): 1.8 per 100,000 (vs. 0.8 overall)
  • These life-threatening complications occur almost exclusively in primary vaccine recipients (first-time vaccination)

The risk increases further with advancing age beyond 60. Research confirms a 2-3 fold higher rate of significant neurologic and multisystem adverse events in those 65-74 years old, with the risk continuing to rise 2. At 87, this patient is in the highest-risk category.

Entresto (Sacubitril/Valsartan) Considerations

The FDA label for Entresto does not contraindicate live vaccines and does not list immunosuppression as an effect 3. Entresto is a neprilysin inhibitor combined with an angiotensin receptor blocker—it is not an immunosuppressive medication. The ACIP guidelines specifically contraindicate yellow fever vaccine for patients on immunosuppressive therapies (high-dose corticosteroids, alkylating drugs, TNF-α inhibitors, etc.), but Entresto does not fall into these categories 1.

Cardiomyopathy Context

While cardiomyopathy itself is not listed as a contraindication to yellow fever vaccine, the combination of advanced age (87) plus underlying cardiac disease creates a particularly vulnerable patient. The serious adverse events from yellow fever vaccine (YEL-AVD and YEL-AND) can cause multisystem organ failure and have mortality rates of 60-65% when they occur.

Clinical Algorithm for Decision-Making

Step 1: Determine necessity of travel

  • Is travel to a yellow fever endemic area absolutely unavoidable?
  • If NO → Do not vaccinate
  • If YES → Proceed to Step 2

Step 2: Assess specific exposure risk

  • What is the destination-specific risk of yellow fever virus exposure?
  • Urban vs. rural travel?
  • Season and current outbreak status?
  • Duration of stay?

Step 3: Risk-benefit calculation

  • High-risk endemic area with active transmission + unavoidable travel → Consider vaccination with informed consent about 8.3/100,000 serious adverse event risk
  • Low-risk area or administrative requirement only → Provide medical waiver, do NOT vaccinate

Step 4: If vaccination is deemed necessary

  • Ensure this is truly first-time vaccination (risk is highest for primary recipients)
  • Observe patient for minimum 15 minutes post-vaccination with epinephrine 1:1,000 immediately available 1
  • Counsel on delayed allergic reactions (can occur hours later)
  • Advise patient to seek immediate care for any neurologic symptoms or systemic illness in the weeks following vaccination

Medical Waiver Approach

For most scenarios at age 87, the preferred approach is a medical waiver 1:

The ACIP guidelines explicitly state: "If travel is unavoidable, the decision to vaccinate travelers aged ≥60 years needs to weigh the risks and benefits of the vaccination in the context of their destination-specific risk for exposure to YFV" 1.

Complete the Medical Contraindication section of the International Certificate of Vaccination or Prophylaxis (ICVP), citing advanced age (87 years) as a precaution with unfavorable risk-benefit ratio 1. Provide a signed, dated exemption letter. Emphasize rigorous mosquito bite prevention: DEET-containing repellents, permethrin-treated clothing, bed nets, and staying in air-conditioned or well-screened accommodations.

Common Pitfalls to Avoid

  1. Don't assume Entresto is immunosuppressive—it is not, and this is not the reason to avoid vaccination
  2. Don't vaccinate simply because a country requires it for entry—many countries accept medical waivers for legitimate contraindications/precautions
  3. Don't underestimate age-related risk—at 87, this patient is at the extreme end of the risk spectrum, far beyond the ≥60 threshold studied
  4. Don't forget that previous yellow fever vaccination changes the equation—if this patient was vaccinated >10 years ago, the risk profile is substantially lower (serious events occur almost exclusively in primary recipients)

Summary of Evidence Quality

The ACIP guidelines 1 represent the highest-quality evidence available (official CDC/MMWR recommendations from 2010, still current). These are supported by VAERS surveillance data and multiple cohort studies. The research evidence 4, 5, 2 consistently confirms elevated risk in elderly populations through both prospective and retrospective analyses.

References

Related Questions

How does annual influenza vaccination reduce mortality in patients with cardiovascular disease (e.g., coronary artery disease, heart failure, hypertension, or prior stroke), especially in those aged ≥ 65 years or with high‑risk cardiac conditions?
Can a six‑day postpartum, breastfeeding patient with edema and suspected peripartum cardiomyopathy be treated with Lasix (furosemide)?
Is it safe to prescribe an angiotensin receptor neprilysin inhibitor (sacubitril/valsartan) for a patient with peripartum cardiomyopathy?
Does the influenza vaccine prevent cardiovascular disease?
What are the ACC guideline recommendations for influenza, pneumococcal, and herpes zoster vaccination in adult patients with established cardiac disease?
What is the appropriate evaluation and management for a woman with elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), severe hypertriglyceridemia, and hypercholesterolemia?
What is the appropriate management of aspiration pneumonitis?
Is estrogen replacement therapy appropriate for a menopausal patient with a prior pulmonary embolism?
What is a comprehensive overview of rheumatic heart disease?
A patient on rosuvastatin (Crestor) 5 mg with baseline triglycerides 203 mg/dL and LDL 155 mg/dL now has triglycerides 196 mg/dL and LDL 80 mg/dL after one year; how should the lipid therapy be adjusted?
Can you provide articles and journal literature for a case report on bacterial epidural abscess with pyogenic spondylodiscitis and concomitant Mycobacterium tuberculosis spondylodiscitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.